1 of 1
Story summary
- Eli Lilly and Company reported strong Q4 2025 results, with revenue of $19.3 billion, up 43% year over year.
- Mounjaro generated $7.41 billion and Zepbound $4.2 billion in Q4 2025, driving growth.
- The company expects 2026 revenue of $80–$83 billion, aided by Medicare coverage for obesity treatments.
- Net income rose to $6.6 billion, up 50% year over year.
